This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Cornell University, University of Notre Dame Du Lac. Active years: 2016-2018.
Company Filing History:
2 out of 2,946 
1 out of 385 
Years Active: 2016-2018
Title: Frederick Maxfield: Innovator in Cholesterol and Lysosomal Storage Disorder Treatments
Introduction
Frederick Maxfield is a notable inventor based in Chappaqua, NY (US). He has made significant contributions to the fields of biochemistry and medicine, particularly in the development of compositions aimed at reducing cholesterol levels and treating lysosomal storage disorders.
Latest Patents
Maxfield holds 2 patents that showcase his innovative approaches. His first patent focuses on "Compositions and their use for removing cholesterol." This invention is directed to compositions that function to remove cholesterol from mammals suffering from elevated cholesterol levels. The composition includes a polysaccharide with at least one cyclic oligosaccharide attached. Additionally, this composition may include at least one cell-targeting agent. The invention also outlines methods for utilizing these compositions to reduce cholesterol and other lipids in affected mammals.
His second patent, "Histone deacetylase inhibitors as therapeutic agents for Niemann-Pick type C disease," relates to lysosomal storage disorders. This patent describes methods for treating Niemann-Pick type C disease using inhibitors of histone deacetylases, particularly class 1 histone deacetylase inhibitors. These methods aim to provide therapeutic solutions for individuals suffering from this condition.
Career Highlights
Frederick Maxfield has had a distinguished career, contributing to significant advancements in medical research. He has worked at prestigious institutions, including Cornell University and the University of Notre Dame Du Lac. His work has been instrumental in developing innovative treatments that address critical health issues.
Collaborations
Throughout his career, Maxfield has collaborated with esteemed colleagues, including J David Warren and Olaf G Wiest. These collaborations have further enriched his research and contributed to the success of his inventions.
Conclusion
Frederick Maxfield's contributions to the fields of cholesterol reduction and lysosomal storage disorder treatments highlight his innovative spirit and dedication to improving health outcomes. His patents reflect a commitment to advancing medical science and providing solutions for complex health challenges.